898552-69-7

Basic information

• Product Name: 4-{3-[5-(4-nitro-phenyl)-furan-2-yl]-5-thioxo-thiazolo[4,5-c]isothiazol-6-yl}-butyric acid ethyl ester
• Synonyms: 4-{3-[5-(4-nitro-phenyl)-furan-2-yl]-5-thioxo-thiazolo[4,5-c]isothiazol-6-yl}-butyric acid ethyl ester
• CAS NO: 898552-69-7
• Molecular Weight: 475.57
• Mol File: 898552-69-7.mol

Chemical Properties

• CAS DataBase Reference: 4-{3-[5-(4-nitro-phenyl)-furan-2-yl]-5-thioxo-thiazolo[4,5-c]isothiazol-6-yl}-butyric acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{3-[5-(4-nitro-phenyl)-furan-2-yl]-5-thioxo-thiazolo[4,5-c]isothiazol-6-yl}-butyric acid ethyl ester(898552-69-7)
• EPA Substance Registry System: 4-{3-[5-(4-nitro-phenyl)-furan-2-yl]-5-thioxo-thiazolo[4,5-c]isothiazol-6-yl}-butyric acid ethyl ester(898552-69-7)

Safety Data

• Hazardous Substances Data: 898552-69-7(Hazardous Substances Data)

Upstream product

• 28123-72-0 2-(4-nitrophenyl)furan 
• 898552-67-5 4-(3-amino-5-thioxo-thiazolo[4,5-c]isothiazol-6-yl)-butyric acid ethyl ester 
• 17126-65-7 E-4ib 
• 898552-90-4 4-(4-amino-5-thiocarbamoyl-2-thioxo-thiazol-3-yl)-butyric acid ethyl ester 
• 898552-89-1 4-(4-amino-5-cyano-2-thioxo-thiazol-3-yl)-butyric acid ethyl ester 

Relevant articles and documents

Rigidified Compounds for Modulating Heparanase Activity

Disclosed are novel rigidified compounds having a rhodanine-like residue and at least one aryl or heteroaryl residue linked to the rhodanine-like residue, whereby a core structure of these compounds, as defined in the specification, is characterized as having one or zero free-to-rotate bonds. Also disclosed are pharmaceutical compositions containing these rigidified compounds and uses thereof for modulating the activity of heparanase and hence in the treatment of heparanase-associated diseases and disorders, and uses thereof for modulating the activity of heparin-binding proteins and hence in the treatment of heparin-binding proteins-associated diseases and disorders as well as in the treatment of medical conditions that are at least partially treatable by rhodanine or a rhodanine analog.